JP2000506880A - シンノリン誘導体及びその使用 - Google Patents

シンノリン誘導体及びその使用

Info

Publication number: JP2000506880A
Authority: JP; Japan
Prior art keywords: alkyl; same; ethyl; formula; hydroxy
Prior art date: 1996-03-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

JP9533220A

Other languages

English (en)

Japanese (ja)

Other versions

JP2000506880A5 (2

Inventor

ピータートーマスアンドリュウ

フランソワアンドレヘンネカンローラン

Original Assignee

ゼネカ・リミテッド

ゼネカファルマソシエテアノニム

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-03-15

Filing date

1997-03-11

Publication date

2000-06-06

1997-03-11 Application filed by ゼネカ・リミテッド, ゼネカファルマソシエテアノニム filed Critical ゼネカ・リミテッド

2000-06-06 Publication of JP2000506880A publication Critical patent/JP2000506880A/ja

2004-11-25 Publication of JP2000506880A5 publication Critical patent/JP2000506880A5/ja

Status Ceased legal-status Critical Current

Links

125000000259 cinnolinyl group Chemical class N1=NC(=CC2=CC=CC=C12)* 0.000 title abstract description 7
-1 hydroxy, fluoro, chloro, methoxy, amino Chemical group 0.000 claims abstract description 462
150000001875 compounds Chemical class 0.000 claims abstract description 212
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 128
239000001257 hydrogen Substances 0.000 claims abstract description 128
150000003839 salts Chemical class 0.000 claims abstract description 109
150000002431 hydrogen Chemical class 0.000 claims abstract description 85
125000005843 halogen group Chemical group 0.000 claims abstract description 72
125000000217 alkyl group Chemical group 0.000 claims abstract description 68
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 56
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 42
230000000694 effects Effects 0.000 claims abstract description 40
125000000623 heterocyclic group Chemical group 0.000 claims abstract description 28
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 26
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 25
241001465754 Metazoa Species 0.000 claims abstract description 19
230000008728 vascular permeability Effects 0.000 claims abstract description 19
239000003814 drug Substances 0.000 claims abstract description 16
238000004519 manufacturing process Methods 0.000 claims abstract description 16
238000011282 treatment Methods 0.000 claims abstract description 16
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
125000001424 substituent group Chemical group 0.000 claims description 64
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 56
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 44
229910052757 nitrogen Inorganic materials 0.000 claims description 34
238000000034 method Methods 0.000 claims description 31
125000003545 alkoxy group Chemical group 0.000 claims description 28
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 25
125000005842 heteroatom Chemical group 0.000 claims description 22
125000004043 oxo group Chemical group O=* 0.000 claims description 21
125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 20
229910052760 oxygen Inorganic materials 0.000 claims description 20
WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 claims description 19
150000001854 cinnolines Chemical class 0.000 claims description 19
229910052717 sulfur Inorganic materials 0.000 claims description 19
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 18
125000004093 cyano group Chemical group *C#N 0.000 claims description 17
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 17
239000002253 acid Substances 0.000 claims description 14
125000004848 alkoxyethyl group Chemical group 0.000 claims description 14
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 12
229910052799 carbon Inorganic materials 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 10
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 9
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 8
LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 claims description 8
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
241000282412 Homo Species 0.000 claims description 7
DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 claims description 7
230000002137 anti-vascular effect Effects 0.000 claims description 7
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 7
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
238000010511 deprotection reaction Methods 0.000 claims description 6
125000002883 imidazolyl group Chemical group 0.000 claims description 6
125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
230000035699 permeability Effects 0.000 claims description 6
125000003386 piperidinyl group Chemical group 0.000 claims description 6
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 5
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 5
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
125000004193 piperazinyl group Chemical group 0.000 claims description 5
125000001425 triazolyl group Chemical group 0.000 claims description 5
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 4
125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 3
125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 3
SQYXDWYTUCHXBJ-UHFFFAOYSA-N 4-fluoro-5-[[6-methoxy-7-(2-methoxyethoxy)cinnolin-4-yl]amino]-2-methylphenol Chemical compound C=12C=C(OC)C(OCCOC)=CC2=NN=CC=1NC1=CC(O)=C(C)C=C1F SQYXDWYTUCHXBJ-UHFFFAOYSA-N 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
150000001721 carbon Chemical group 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
239000006187 pill Substances 0.000 claims description 3
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
125000003226 pyrazolyl group Chemical group 0.000 claims description 2
WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 2
125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
125000000168 pyrrolyl group Chemical group 0.000 claims description 2
XZPZVFAARDDFLG-UHFFFAOYSA-N 3-methoxycinnoline Chemical compound C1=CC=C2N=NC(OC)=CC2=C1 XZPZVFAARDDFLG-UHFFFAOYSA-N 0.000 claims 1
CCCDJBZHLQCWCA-UHFFFAOYSA-N 3-pyridin-4-ylcinnoline Chemical compound N1=CC=C(C=C1)C=1N=NC2=CC=CC=C2C1 CCCDJBZHLQCWCA-UHFFFAOYSA-N 0.000 claims 1
241000894007 species Species 0.000 claims 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract description 26
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract description 26
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 11
206010028980 Neoplasm Diseases 0.000 abstract description 11
230000001772 anti-angiogenic effect Effects 0.000 abstract description 8
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 6
201000011510 cancer Diseases 0.000 abstract description 6
201000010099 disease Diseases 0.000 abstract description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
206010039073 rheumatoid arthritis Diseases 0.000 abstract description 5
229920006395 saturated elastomer Polymers 0.000 abstract description 4
125000004455 (C1-C3) alkylthio group Chemical group 0.000 abstract 1
125000004423 acyloxy group Chemical group 0.000 abstract 1
125000002837 carbocyclic group Chemical group 0.000 abstract 1
125000005647 linker group Chemical group 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 108
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 85
239000000243 solution Substances 0.000 description 61
239000007858 starting material Substances 0.000 description 58
239000007787 solid Substances 0.000 description 56
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 53
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 51
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 47
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
238000006243 chemical reaction Methods 0.000 description 44
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
239000000203 mixture Substances 0.000 description 36
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
JYVLIDXNZAXMDK-UHFFFAOYSA-N pentan-2-ol Chemical compound CCCC(C)O JYVLIDXNZAXMDK-UHFFFAOYSA-N 0.000 description 30
238000000921 elemental analysis Methods 0.000 description 28
239000002904 solvent Substances 0.000 description 28
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 25
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
238000003756 stirring Methods 0.000 description 19
239000012267 brine Substances 0.000 description 18
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 18
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 16
239000002585 base Substances 0.000 description 16
238000001704 evaporation Methods 0.000 description 16
239000012044 organic layer Substances 0.000 description 16
230000008020 evaporation Effects 0.000 description 15
125000001153 fluoro group Chemical group F* 0.000 description 15
238000010992 reflux Methods 0.000 description 15
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
210000004027 cell Anatomy 0.000 description 14
238000011156 evaluation Methods 0.000 description 14
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 14
238000001816 cooling Methods 0.000 description 13
102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 12
108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
239000003480 eluent Substances 0.000 description 11
238000003818 flash chromatography Methods 0.000 description 11
238000010438 heat treatment Methods 0.000 description 11
238000012360 testing method Methods 0.000 description 11
125000001309 chloro group Chemical group Cl* 0.000 description 10
239000003102 growth factor Substances 0.000 description 10
239000000047 product Substances 0.000 description 10
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 10
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 9
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 9
230000002349 favourable effect Effects 0.000 description 9
230000008018 melting Effects 0.000 description 9
238000002844 melting Methods 0.000 description 9
229910000027 potassium carbonate Inorganic materials 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
JQBSTRWZKVHRHE-UHFFFAOYSA-N cinnoline;hydrochloride Chemical compound Cl.N1=NC=CC2=CC=CC=C21 JQBSTRWZKVHRHE-UHFFFAOYSA-N 0.000 description 8
229940088598 enzyme Drugs 0.000 description 8
239000012442 inert solvent Substances 0.000 description 8
239000008101 lactose Substances 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
239000003208 petroleum Substances 0.000 description 8
239000011541 reaction mixture Substances 0.000 description 8
230000009467 reduction Effects 0.000 description 8
239000000725 suspension Substances 0.000 description 8
241000700159 Rattus Species 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
238000004587 chromatography analysis Methods 0.000 description 7
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 7
239000003701 inert diluent Substances 0.000 description 7
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 7
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 7
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
FNYDIAAMUCQQDE-UHFFFAOYSA-N 4-methylbenzene-1,3-diol Chemical compound CC1=CC=C(O)C=C1O FNYDIAAMUCQQDE-UHFFFAOYSA-N 0.000 description 6
HEAQOCBITATQEW-UHFFFAOYSA-N 5-amino-4-fluoro-2-methylphenol Chemical compound CC1=CC(F)=C(N)C=C1O HEAQOCBITATQEW-UHFFFAOYSA-N 0.000 description 6
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 6
NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 6
UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
238000000605 extraction Methods 0.000 description 6
238000001914 filtration Methods 0.000 description 6
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
241000701447 unidentified baculovirus Species 0.000 description 6
229920002785 Croscarmellose sodium Polymers 0.000 description 5
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 5
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 5
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
230000033115 angiogenesis Effects 0.000 description 5
125000003118 aryl group Chemical group 0.000 description 5
239000002775 capsule Substances 0.000 description 5
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Natural products OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
238000007796 conventional method Methods 0.000 description 5
229960001681 croscarmellose sodium Drugs 0.000 description 5
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
229910017604 nitric acid Inorganic materials 0.000 description 5
235000010288 sodium nitrite Nutrition 0.000 description 5
239000000126 substance Substances 0.000 description 5
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
BZQJRBWTDBHAHT-UHFFFAOYSA-N 4-chloro-6-methoxycinnolin-7-ol Chemical compound C1=NN=C2C=C(O)C(OC)=CC2=C1Cl BZQJRBWTDBHAHT-UHFFFAOYSA-N 0.000 description 4
AFZLCOLNTRPSIF-UHFFFAOYSA-N 5-amino-2-chloro-4-fluorophenol Chemical compound NC1=CC(O)=C(Cl)C=C1F AFZLCOLNTRPSIF-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
102400001368 Epidermal growth factor Human genes 0.000 description 4
101800003838 Epidermal growth factor Proteins 0.000 description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
101100372761 Mus musculus Flt1 gene Proteins 0.000 description 4
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
229910052783 alkali metal Inorganic materials 0.000 description 4
125000000304 alkynyl group Chemical group 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000001086 cytosolic effect Effects 0.000 description 4
238000006193 diazotization reaction Methods 0.000 description 4
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
229940116977 epidermal growth factor Drugs 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000010410 layer Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
150000007522 mineralic acids Chemical class 0.000 description 4
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 4
239000002953 phosphate buffered saline Substances 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
125000000335 thiazolyl group Chemical group 0.000 description 4
238000010626 work up procedure Methods 0.000 description 4
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
ZACFYFJWKOKECW-UHFFFAOYSA-N 4-chloro-6,7-dimethoxycinnoline;hydrochloride Chemical compound Cl.N1=CC(Cl)=C2C=C(OC)C(OC)=CC2=N1 ZACFYFJWKOKECW-UHFFFAOYSA-N 0.000 description 3
JGCWYNFSCBNODV-UHFFFAOYSA-N 4-chloro-7-methoxycinnoline;hydrochloride Chemical compound Cl.ClC1=CN=NC2=CC(OC)=CC=C21 JGCWYNFSCBNODV-UHFFFAOYSA-N 0.000 description 3
RSHVJZUBABFJRL-UHFFFAOYSA-N 4-fluoro-2-methyl-5-nitrophenol Chemical compound CC1=CC(F)=C([N+]([O-])=O)C=C1O RSHVJZUBABFJRL-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 3
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
206010003210 Arteriosclerosis Diseases 0.000 description 3
208000037260 Atherosclerotic Plaque Diseases 0.000 description 3
239000005711 Benzoic acid Substances 0.000 description 3
QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
239000005947 Dimethoate Substances 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
208000007766 Kaposi sarcoma Diseases 0.000 description 3
238000005481 NMR spectroscopy Methods 0.000 description 3
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
108091000080 Phosphotransferase Proteins 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
229910052784 alkaline earth metal Inorganic materials 0.000 description 3
229940100198 alkylating agent Drugs 0.000 description 3
239000002168 alkylating agent Substances 0.000 description 3
235000010233 benzoic acid Nutrition 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
125000001246 bromo group Chemical group Br* 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
239000006071 cream Substances 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
150000002170 ethers Chemical class 0.000 description 3
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
239000000284 extract Substances 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
230000012010 growth Effects 0.000 description 3
201000011066 hemangioma Diseases 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000013067 intermediate product Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
229940050176 methyl chloride Drugs 0.000 description 3
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
150000007524 organic acids Chemical class 0.000 description 3
102000020233 phosphotransferase Human genes 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
125000004076 pyridyl group Chemical group 0.000 description 3
102000027426 receptor tyrosine kinases Human genes 0.000 description 3
108091008598 receptor tyrosine kinases Proteins 0.000 description 3
238000007363 ring formation reaction Methods 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000001488 sodium phosphate Substances 0.000 description 3
229910000162 sodium phosphate Inorganic materials 0.000 description 3
239000000758 substrate Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
210000004291 uterus Anatomy 0.000 description 3
239000008215 water for injection Substances 0.000 description 3
MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 2
HRUAWSQBQLYDKH-UHFFFAOYSA-N 1-(3-methoxy-4-phenylmethoxyphenyl)ethanone Chemical compound COC1=CC(C(C)=O)=CC=C1OCC1=CC=CC=C1 HRUAWSQBQLYDKH-UHFFFAOYSA-N 0.000 description 2
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 2
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
VVMXHXQJKRZVKL-UHFFFAOYSA-N 2-bromo-4-fluoro-5-[[6-methoxy-7-(2-methoxyethoxy)cinnolin-4-yl]amino]phenol Chemical compound C=12C=C(OC)C(OCCOC)=CC2=NN=CC=1NC1=CC(O)=C(Br)C=C1F VVMXHXQJKRZVKL-UHFFFAOYSA-N 0.000 description 2
JDPAKZCGVWMFFH-UHFFFAOYSA-N 2-chloro-4-fluoro-5-[[6-methoxy-7-(2-methoxyethoxy)cinnolin-4-yl]amino]phenol Chemical compound C=12C=C(OC)C(OCCOC)=CC2=NN=CC=1NC1=CC(O)=C(Cl)C=C1F JDPAKZCGVWMFFH-UHFFFAOYSA-N 0.000 description 2
MQZAJDNVSWBAST-UHFFFAOYSA-N 2-fluoro-4-methyl-5-phenylmethoxyphenol Chemical compound CC1=CC(F)=C(O)C=C1OCC1=CC=CC=C1 MQZAJDNVSWBAST-UHFFFAOYSA-N 0.000 description 2
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
BSNACPZTQQUTOV-UHFFFAOYSA-N 3-(2-methoxyethoxy)cinnoline Chemical compound C1=CC=C2N=NC(OCCOC)=CC2=C1 BSNACPZTQQUTOV-UHFFFAOYSA-N 0.000 description 2
LMVNXAFDYCZSRC-UHFFFAOYSA-N 4-[(4-chloro-6-methoxycinnolin-7-yl)oxymethyl]-2-methyl-1,3-thiazole Chemical compound COC1=CC2=C(Cl)C=NN=C2C=C1OCC1=CSC(C)=N1 LMVNXAFDYCZSRC-UHFFFAOYSA-N 0.000 description 2
FSJHRGVMCMBKPH-UHFFFAOYSA-N 4-[3-(4-chloro-6-methoxycinnolin-7-yl)oxypropyl]morpholine Chemical compound COC1=CC2=C(Cl)C=NN=C2C=C1OCCCN1CCOCC1 FSJHRGVMCMBKPH-UHFFFAOYSA-N 0.000 description 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
CSFDTBRRIBJILD-UHFFFAOYSA-N 4-chloro-2-fluoroaniline Chemical compound NC1=CC=C(Cl)C=C1F CSFDTBRRIBJILD-UHFFFAOYSA-N 0.000 description 2
DPVLKMCULFVIPD-UHFFFAOYSA-N 4-chloro-6-methoxy-7-[(1-methylimidazol-2-yl)methoxy]cinnoline Chemical compound COC1=CC2=C(Cl)C=NN=C2C=C1OCC1=NC=CN1C DPVLKMCULFVIPD-UHFFFAOYSA-N 0.000 description 2
KAGKNXCTQZTTRX-UHFFFAOYSA-N 4-chloro-6-methoxy-7-phenylmethoxycinnoline;hydrochloride Chemical compound Cl.COC1=CC2=C(Cl)C=NN=C2C=C1OCC1=CC=CC=C1 KAGKNXCTQZTTRX-UHFFFAOYSA-N 0.000 description 2
OAODBUGQAKBDFF-UHFFFAOYSA-N 4-fluoro-5-[[6-methoxy-7-(3-morpholin-4-ylpropoxy)cinnolin-4-yl]amino]-2-methylphenol Chemical compound C1=NN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1NC1=CC(O)=C(C)C=C1F OAODBUGQAKBDFF-UHFFFAOYSA-N 0.000 description 2
VBGCBVGWDHRGCH-UHFFFAOYSA-N 4-fluoro-5-[[6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)cinnolin-4-yl]amino]-2-methylphenol Chemical compound C1=NN=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1=CC(O)=C(C)C=C1F VBGCBVGWDHRGCH-UHFFFAOYSA-N 0.000 description 2
HGAXCWYCCKEHHW-UHFFFAOYSA-N 4-fluoro-5-[[6-methoxy-7-[(2-methyl-1,3-thiazol-4-yl)methoxy]cinnolin-4-yl]amino]-2-methylphenol Chemical compound C1=NN=C2C=C(OCC=3N=C(C)SC=3)C(OC)=CC2=C1NC1=CC(O)=C(C)C=C1F HGAXCWYCCKEHHW-UHFFFAOYSA-N 0.000 description 2
DBFYESDCPWWCHN-UHFFFAOYSA-N 5-amino-2-methylphenol Chemical compound CC1=CC=C(N)C=C1O DBFYESDCPWWCHN-UHFFFAOYSA-N 0.000 description 2
CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 2
MIUNNXRSSLYMOV-UHFFFAOYSA-N 6,7-dimethoxy-1h-cinnolin-4-one Chemical compound N1=CC(O)=C2C=C(OC)C(OC)=CC2=N1 MIUNNXRSSLYMOV-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
206010051113 Arterial restenosis Diseases 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
108060006698 EGF receptor Proteins 0.000 description 2
102000001301 EGF receptor Human genes 0.000 description 2
241000196324 Embryophyta Species 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
241001553014 Myrsine salicina Species 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
229910021627 Tin(IV) chloride Inorganic materials 0.000 description 2
102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 2
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000009471 action Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
208000038016 acute inflammation Diseases 0.000 description 2
230000006022 acute inflammation Effects 0.000 description 2
125000003342 alkenyl group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
DFYRUELUNQRZTB-UHFFFAOYSA-N apocynin Chemical compound COC1=CC(C(C)=O)=CC=C1O DFYRUELUNQRZTB-UHFFFAOYSA-N 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
125000004104 aryloxy group Chemical group 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
150000004649 carbonic acid derivatives Chemical class 0.000 description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
229960001701 chloroform Drugs 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
125000004122 cyclic group Chemical group 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
239000000824 cytostatic agent Substances 0.000 description 2
230000001085 cytostatic effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
229950002007 estradiol benzoate Drugs 0.000 description 2
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
239000012467 final product Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000000417 fungicide Substances 0.000 description 2
230000002140 halogenating effect Effects 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
238000005984 hydrogenation reaction Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
239000011968 lewis acid catalyst Substances 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
QEWYKACRFQMRMB-UHFFFAOYSA-N monofluoroacetic acid Natural products OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
239000007981 phosphate-citrate buffer Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
239000011574 phosphorus Substances 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
125000005936 piperidyl group Chemical group 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
229940068918 polyethylene glycol 400 Drugs 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000008569 process Effects 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
239000003586 protic polar solvent Substances 0.000 description 2
238000000746 purification Methods 0.000 description 2
125000002098 pyridazinyl group Chemical group 0.000 description 2
230000002207 retinal effect Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
229960001922 sodium perborate Drugs 0.000 description 2
YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
125000001544 thienyl group Chemical group 0.000 description 2
HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
230000006444 vascular growth Effects 0.000 description 2
239000013598 vector Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
KIQNTUVEIYAMDA-UHFFFAOYSA-N (4-fluoro-2-methylphenyl) methyl carbonate Chemical compound COC(=O)OC1=CC=C(F)C=C1C KIQNTUVEIYAMDA-UHFFFAOYSA-N 0.000 description 1
LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
PAKRFYHSUARJBW-UHFFFAOYSA-N (bromo-chloro-methoxymethoxy)benzene Chemical compound ClC(OC1=CC=CC=C1)(OC)Br PAKRFYHSUARJBW-UHFFFAOYSA-N 0.000 description 1
SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 1
WMXFNCKPYCAIQW-UHFFFAOYSA-N 1,2-dimethoxy-3-methylbenzene Chemical compound COC1=CC=CC(C)=C1OC WMXFNCKPYCAIQW-UHFFFAOYSA-N 0.000 description 1
GIWQSPITLQVMSG-UHFFFAOYSA-N 1,2-dimethylimidazole Chemical compound CC1=NC=CN1C GIWQSPITLQVMSG-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
XQKKKDKTZJGWDN-UHFFFAOYSA-N 1-fluoro-5-methyl-2-nitro-4-phenylmethoxybenzene Chemical compound CC1=CC(F)=C([N+]([O-])=O)C=C1OCC1=CC=CC=C1 XQKKKDKTZJGWDN-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
GXVUZYLYWKWJIM-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanamine Chemical compound NCCOCCN GXVUZYLYWKWJIM-UHFFFAOYSA-N 0.000 description 1
IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
GSFNQBFZFXUTBN-UHFFFAOYSA-N 2-chlorothiophene Chemical compound ClC1=CC=CS1 GSFNQBFZFXUTBN-UHFFFAOYSA-N 0.000 description 1
PSSHBBRBQXIAGO-UHFFFAOYSA-N 2-fluoro-4-methyl-5-phenylmethoxyaniline Chemical compound CC1=CC(F)=C(N)C=C1OCC1=CC=CC=C1 PSSHBBRBQXIAGO-UHFFFAOYSA-N 0.000 description 1
IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
JODYTPOPHDEHOP-UHFFFAOYSA-N 4,6-dichlorocinnoline Chemical compound N1=NC=C(Cl)C2=CC(Cl)=CC=C21 JODYTPOPHDEHOP-UHFFFAOYSA-N 0.000 description 1
DUGGLGCFHYZIQE-UHFFFAOYSA-N 4-(2,6-dimethylphenoxy)-6,7-dimethoxycinnoline Chemical compound C=12C=C(OC)C(OC)=CC2=NN=CC=1OC1=C(C)C=CC=C1C DUGGLGCFHYZIQE-UHFFFAOYSA-N 0.000 description 1
PIAZYBLGBSMNLX-UHFFFAOYSA-N 4-(3-chloropropyl)morpholine Chemical compound ClCCCN1CCOCC1 PIAZYBLGBSMNLX-UHFFFAOYSA-N 0.000 description 1
AQBBZYVPKBIILN-UHFFFAOYSA-N 4-(chloromethyl)-2-methyl-1,3-thiazole Chemical compound CC1=NC(CCl)=CS1 AQBBZYVPKBIILN-UHFFFAOYSA-N 0.000 description 1
GZRMNMGWNKSANY-UHFFFAOYSA-N 4-bromo-2-fluoroaniline Chemical compound NC1=CC=C(Br)C=C1F GZRMNMGWNKSANY-UHFFFAOYSA-N 0.000 description 1
KFRPNAXFNZCHSZ-UHFFFAOYSA-N 4-chloro-6-methoxy-7-(2-methoxyethoxy)cinnoline Chemical compound N1=CC(Cl)=C2C=C(OC)C(OCCOC)=CC2=N1 KFRPNAXFNZCHSZ-UHFFFAOYSA-N 0.000 description 1
BBNYOUOJNPSDDX-UHFFFAOYSA-N 4-chloro-6-methoxy-7-(pyridin-4-ylmethoxy)cinnoline;hydrochloride Chemical compound Cl.COC1=CC2=C(Cl)C=NN=C2C=C1OCC1=CC=NC=C1 BBNYOUOJNPSDDX-UHFFFAOYSA-N 0.000 description 1
DIWXANCWZVIXNA-UHFFFAOYSA-N 4-chloro-6-methoxy-7-[2-(2-methoxyethoxy)ethoxy]cinnoline Chemical compound N1=CC(Cl)=C2C=C(OC)C(OCCOCCOC)=CC2=N1 DIWXANCWZVIXNA-UHFFFAOYSA-N 0.000 description 1
CSXQFMJTNPXPNK-UHFFFAOYSA-N 4-chloro-7-(2-methoxyethoxy)cinnoline Chemical compound ClC1=CN=NC2=CC(OCCOC)=CC=C21 CSXQFMJTNPXPNK-UHFFFAOYSA-N 0.000 description 1
BAVQBPIGVBGELE-UHFFFAOYSA-N 4-chloro-7-methoxycinnoline Chemical compound ClC1=CN=NC2=CC(OC)=CC=C21 BAVQBPIGVBGELE-UHFFFAOYSA-N 0.000 description 1
AUZNQQFVTCXCLP-UHFFFAOYSA-N 4-chlorocinnolin-7-ol Chemical compound ClC1=CN=NC2=CC(O)=CC=C21 AUZNQQFVTCXCLP-UHFFFAOYSA-N 0.000 description 1
GKQDDKKGDIVDAG-UHFFFAOYSA-N 4-fluoro-2-methylphenol Chemical compound CC1=CC(F)=CC=C1O GKQDDKKGDIVDAG-UHFFFAOYSA-N 0.000 description 1
HWPILQISNXLNJI-UHFFFAOYSA-N 4-fluoro-5-[6-methoxy-7-(2-methoxyethoxy)cinnolin-4-yl]oxy-2-methylphenol Chemical compound C=12C=C(OC)C(OCCOC)=CC2=NN=CC=1OC1=CC(O)=C(C)C=C1F HWPILQISNXLNJI-UHFFFAOYSA-N 0.000 description 1
SDTKSHQSQUDESU-UHFFFAOYSA-N 4-fluoro-5-[[6-methoxy-7-[(1-methylimidazol-2-yl)methoxy]cinnolin-4-yl]amino]-2-methylphenol Chemical compound C1=NN=C2C=C(OCC=3N(C=CN=3)C)C(OC)=CC2=C1NC1=CC(O)=C(C)C=C1F SDTKSHQSQUDESU-UHFFFAOYSA-N 0.000 description 1
125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
CMTBUGQJXIZASA-UHFFFAOYSA-N 4-phenoxycinnoline Chemical compound C=1N=NC2=CC=CC=C2C=1OC1=CC=CC=C1 CMTBUGQJXIZASA-UHFFFAOYSA-N 0.000 description 1
RYBQDEXJIRIOBT-UHFFFAOYSA-N 4-phenylsulfanylcinnoline Chemical compound C=1N=NC2=CC=CC=C2C=1SC1=CC=CC=C1 RYBQDEXJIRIOBT-UHFFFAOYSA-N 0.000 description 1
NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
MRWRKNRDHHLEPA-UHFFFAOYSA-N 5-amino-2-bromo-4-fluorophenol Chemical compound NC1=CC(O)=C(Br)C=C1F MRWRKNRDHHLEPA-UHFFFAOYSA-N 0.000 description 1
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
SQIQXPUTYJSZFS-UHFFFAOYSA-N 6,7-dimethoxycinnoline Chemical compound C1=NN=C2C=C(OC)C(OC)=CC2=C1 SQIQXPUTYJSZFS-UHFFFAOYSA-N 0.000 description 1
YTSGHFHNSVAEEF-UHFFFAOYSA-N 6-chloro-4-phenoxycinnoline Chemical compound C12=CC(Cl)=CC=C2N=NC=C1OC1=CC=CC=C1 YTSGHFHNSVAEEF-UHFFFAOYSA-N 0.000 description 1
XCDVODGJEZTOBC-UHFFFAOYSA-N 6-methoxy-1h-cinnolin-4-one Chemical compound N1=NC=C(O)C2=CC(OC)=CC=C21 XCDVODGJEZTOBC-UHFFFAOYSA-N 0.000 description 1
NIEWYVLVFPOEEC-UHFFFAOYSA-N 6-methoxy-7-(2-methoxyethoxy)-1h-cinnolin-4-one Chemical compound N1=CC(O)=C2C=C(OC)C(OCCOC)=CC2=N1 NIEWYVLVFPOEEC-UHFFFAOYSA-N 0.000 description 1
FXTMGPTVSXTWQM-UHFFFAOYSA-N 6-methoxy-7-phenylmethoxy-1h-cinnolin-4-one Chemical compound COC1=CC2=C(O)C=NN=C2C=C1OCC1=CC=CC=C1 FXTMGPTVSXTWQM-UHFFFAOYSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000012936 Angiostatins Human genes 0.000 description 1
108010079709 Angiostatins Proteins 0.000 description 1
241000156724 Antirhea Species 0.000 description 1
101100313763 Arabidopsis thaliana TIM22-2 gene Proteins 0.000 description 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
SYQAXYKVXZOYGO-UHFFFAOYSA-N CC1=CC(=C(C=C1)NOCC2=CC=CC=C2)F Chemical compound CC1=CC(=C(C=C1)NOCC2=CC=CC=C2)F SYQAXYKVXZOYGO-UHFFFAOYSA-N 0.000 description 1
JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
241000255925 Diptera Species 0.000 description 1
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
241000975394 Evechinus chloroticus Species 0.000 description 1
101150009958 FLT4 gene Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
108010069236 Goserelin Proteins 0.000 description 1
102000009465 Growth Factor Receptors Human genes 0.000 description 1
108010009202 Growth Factor Receptors Proteins 0.000 description 1
108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
102100021866 Hepatocyte growth factor Human genes 0.000 description 1
102100039875 Histone H3-7 Human genes 0.000 description 1
101001035307 Homo sapiens Histone H3-7 Proteins 0.000 description 1
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
108010047852 Integrin alphaVbeta3 Proteins 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
241001082241 Lythrum hyssopifolia Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
208000022873 Ocular disease Diseases 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000013566 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
102100024028 Progonadoliberin-1 Human genes 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
101100226846 Strongylocentrotus purpuratus EGF3 gene Proteins 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
229910052776 Thorium Inorganic materials 0.000 description 1
101710183280 Topoisomerase Proteins 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
108091008605 VEGF receptors Proteins 0.000 description 1
102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
241000863480 Vinca Species 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 1
230000000895 acaricidal effect Effects 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
229960001456 adenosine triphosphate Drugs 0.000 description 1
150000003838 adenosines Chemical class 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
229910000102 alkali metal hydride Inorganic materials 0.000 description 1
150000008046 alkali metal hydrides Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
229910000272 alkali metal oxide Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002456 anti-arthritic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940034982 antineoplastic agent Drugs 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
229960000997 bicalutamide Drugs 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000009835 boiling Methods 0.000 description 1
BGECDVWSWDRFSP-UHFFFAOYSA-N borazine Chemical compound B1NBNBN1 BGECDVWSWDRFSP-UHFFFAOYSA-N 0.000 description 1
JAMFGQBENKSWOF-UHFFFAOYSA-N bromo(methoxy)methane Chemical compound COCBr JAMFGQBENKSWOF-UHFFFAOYSA-N 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
239000001273 butane Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
230000003185 calcium uptake Effects 0.000 description 1
244000309466 calf Species 0.000 description 1
230000009400 cancer invasion Effects 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000004020 conductor Substances 0.000 description 1
SXTLQDJHRPXDSB-UHFFFAOYSA-N copper;dinitrate;trihydrate Chemical compound O.O.O.[Cu+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O SXTLQDJHRPXDSB-UHFFFAOYSA-N 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229960000978 cyproterone acetate Drugs 0.000 description 1
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 1
229960003887 dichlorophen Drugs 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
229950004203 droloxifene Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000013020 embryo development Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
239000002024 ethyl acetate extract Substances 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
229960000255 exemestane Drugs 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
229960004039 finasteride Drugs 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
229950004696 flusalan Drugs 0.000 description 1
229960002074 flutamide Drugs 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
229960003690 goserelin acetate Drugs 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
238000007327 hydrogenolysis reaction Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
239000005457 ice water Substances 0.000 description 1
229960000908 idarubicin Drugs 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
239000002917 insecticide Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
229960003881 letrozole Drugs 0.000 description 1
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000006166 lysate Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960004961 mechlorethamine Drugs 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
229960004296 megestrol acetate Drugs 0.000 description 1
RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
LPZVNQCTTQCWRT-UHFFFAOYSA-N n-(3-chlorophenyl)-6,7-dimethoxycinnolin-4-amine Chemical compound C=12C=C(OC)C(OC)=CC2=NN=CC=1NC1=CC=CC(Cl)=C1 LPZVNQCTTQCWRT-UHFFFAOYSA-N 0.000 description 1
YZXNNALVXDVBHP-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-(3-morpholin-4-ylpropoxy)cinnolin-4-amine;hydrochloride Chemical compound Cl.C1=NN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F YZXNNALVXDVBHP-UHFFFAOYSA-N 0.000 description 1
SHEPMGJUADNTDC-UHFFFAOYSA-N n-(4-chloro-2-fluorophenyl)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)cinnolin-4-amine;hydrochloride Chemical compound Cl.C1=NN=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F SHEPMGJUADNTDC-UHFFFAOYSA-N 0.000 description 1
OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 1
BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000018791 negative regulation of catalytic activity Effects 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
229960002653 nilutamide Drugs 0.000 description 1
XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000002357 osmotic agent Substances 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
229910000073 phosphorus hydride Inorganic materials 0.000 description 1
UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
150000003057 platinum Chemical class 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
PTMBWNZJOQBTBK-UHFFFAOYSA-N pyridin-4-ylmethanol Chemical compound OCC1=CC=NC=C1 PTMBWNZJOQBTBK-UHFFFAOYSA-N 0.000 description 1
JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
229960004622 raloxifene Drugs 0.000 description 1
229920005604 random copolymer Polymers 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000012552 review Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
229910001948 sodium oxide Inorganic materials 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000010025 steaming Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
FWMUJAIKEJWSSY-UHFFFAOYSA-N sulfur dichloride Chemical compound ClSCl FWMUJAIKEJWSSY-UHFFFAOYSA-N 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
238000003419 tautomerization reaction Methods 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
229940063683 taxotere Drugs 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229960003433 thalidomide Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
229910052722 tritium Inorganic materials 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1
230000029663 wound healing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

JP9533220A 1996-03-15 1997-03-11 シンノリン誘導体及びその使用 Ceased JP2000506880A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP96400533		1996-03-15
EP96400533.4		1996-03-15
PCT/GB1997/000650 WO1997034876A1 (en)	1996-03-15	1997-03-11	Cinnoline derivatives and use as medicine

Publications (2)

Publication Number	Publication Date
JP2000506880A true JP2000506880A (ja)	2000-06-06
JP2000506880A5 JP2000506880A5 (2)	2004-11-25

Family

ID=8225232

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP9533220A Ceased JP2000506880A (ja)	1996-03-15	1997-03-11	シンノリン誘導体及びその使用

Country Status (6)

Country	Link
US (2)	US6514971B1 (2)
EP (1)	EP0888310B1 (2)
JP (1)	JP2000506880A (2)
AU (1)	AU2103097A (2)
DE (1)	DE69734149T2 (2)
WO (1)	WO1997034876A1 (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002522535A (ja) *	1998-08-11	2002-07-23	ノバルティスアクチエンゲゼルシャフト	血管形成阻害活性を有するイソキノリン誘導体
JP2008512375A (ja) *	2004-09-03	2008-04-24	メモリファーマセチカルコーポレーション	精神医学的又は神経学的症候群の治療用のホスホジエステラーゼ１０阻害剤としての４−置換４，６−ジアルコキシ−シンノリン誘導体

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5504074A (en) *	1993-08-06	1996-04-02	Children's Medical Center Corporation	Estrogenic compounds as anti-angiogenic agents
US20040214807A1 (en) *	1993-08-06	2004-10-28	D'amato Robert J.	Estrogenic compounds as anti-mitotic agents
US6908910B2 (en)	1993-08-06	2005-06-21	The Children's Medical Center Corporation	Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) *	1995-10-23	2002-02-12	The Children's Medical Center Corporation	Therapeutic antiangiogenic endostatin compositions
EP0888310B1 (en) *	1996-03-15	2005-09-07	AstraZeneca AB	Cinnoline derivatives and use as medicine
GB9707800D0 (en)	1996-05-06	1997-06-04	Zeneca Ltd	Chemical compounds
GB9718972D0 (en)	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
KR100567649B1 (ko)	1996-09-25	2006-04-05	아스트라제네카 유케이 리미티드	혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
WO1999010349A1 (en)	1997-08-22	1999-03-04	Zeneca Limited	Oxindolylquinazoline derivatives as angiogenesis inhibitors
US20020002294A1 (en) *	1997-09-24	2002-01-03	D' Amato Robert J.	Estrogenic compounds as antiangiogenic agents
WO2000009098A2 (en) *	1998-08-13	2000-02-24	Novartis Ag	Method for treating ocular neovascular diseases
UA71971C2 (en)	1999-06-04	2005-01-17	Agoron Pharmaceuticals Inc	Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
PE20010306A1 (es) *	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US7141581B2 (en)	1999-07-02	2006-11-28	Agouron Pharmaceuticals, Inc.	Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
TWI262914B (en)	1999-07-02	2006-10-01	Agouron Pharma	Compounds and pharmaceutical compositions for inhibiting protein kinases
US6271233B1 (en)	1999-08-10	2001-08-07	Ciba Vision Corporation	Method for treating ocular neovascular diseases
US7087592B1 (en) *	1999-08-23	2006-08-08	Entre Med, Inc.	Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
CZ301689B6 (cs)	1999-11-05	2010-05-26	Astrazeneca Ab	Derivát chinazolinu a farmaceutický prostredek, který ho obsahuje
YU54202A (sh)	2000-01-18	2006-01-16	Agouron Pharmaceuticals Inc.	Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
HN2001000008A (es)	2000-01-21	2003-12-11	Inc Agouron Pharmaceuticals	Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
JP2003521543A (ja)	2000-02-07	2003-07-15	アボットゲーエムベーハーウントカンパニーカーゲー	２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
PT1254138E (pt) *	2000-02-09	2005-09-30	Novartis Ag	Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf
AU2001235804A1 (en) *	2000-03-06	2001-09-17	Astrazeneca Ab	Therapy
GB0008269D0 (en) *	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
ES2267748T3 (es)	2000-04-07	2007-03-16	Astrazeneca Ab	Compuestos de quinazolina.
JP2004501083A (ja)	2000-04-18	2004-01-15	アゴーロン・ファーマシューティカルズ・インコーポレイテッド	プロテインキナーゼを阻害するためのピラゾール
US6995278B2 (en) *	2000-08-18	2006-02-07	Entre Med, Inc.	Antiangiogenic agents
US7135581B2 (en) *	2000-08-18	2006-11-14	Entremed, Inc.	Antiangiogenic agents
US20050192258A1 (en) *	2000-08-18	2005-09-01	Agoston Gregory E.	Antiangiogenic agents
ATE295354T1 (de)	2000-08-18	2005-05-15	Agouron Pharma	Heterozyklische-hydroximino-fluorene und ihre verwendung zur inhibierung von proteinkinasen
EP1313734B1 (en)	2000-09-01	2009-11-11	Novartis Vaccines and Diagnostics, Inc.	Aza heterocyclic derivatives and their therapeutic use
CZ304344B6 (cs) *	2000-09-11	2014-03-19	Novartis Vaccines & Diagnostics, Inc.	Chinolinonový derivát a jeho použití a farmaceutický prostředek s obsahem tohoto derivátu
MXPA03008560A (es)	2001-03-22	2004-06-30	Abbot Gmbh & Co Kg	Pirazolopirimidinas como agentes terapeuticos.
HN2002000156A (es)	2001-07-06	2003-11-27	Inc Agouron Pharmaceuticals	Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
WO2003063791A2 (en) *	2002-01-30	2003-08-07	Entremed, Inc.	Non-steroidal analogs of 2-methoxyestradiol
JP4608215B2 (ja) *	2002-02-01	2011-01-12	アストラゼネカアクチボラグ	キナゾリン化合物
UA77303C2 (en)	2002-06-14	2006-11-15	Pfizer	Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
EP2280003B1 (en)	2002-07-15	2014-04-02	Symphony Evolution, Inc.	Process for preparing receptor-type kinase modulators
US7825132B2 (en)	2002-08-23	2010-11-02	Novartis Vaccines And Diagnostics, Inc.	Inhibition of FGFR3 and treatment of multiple myeloma
CA2496164C (en)	2002-08-23	2010-11-09	Chiron Corporation	Benzimidazole quinolinones and uses thereof
RU2350618C2 (ru) *	2002-11-04	2009-03-27	Астразенека Аб	ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
US7268137B2 (en) *	2002-11-07	2007-09-11	Campochiaro Peter A	Ocular therapy
AU2003290699B2 (en)	2002-11-13	2009-08-27	Novartis Vaccines And Diagnostics, Inc.	Methods of treating cancer and related methods
WO2004056806A1 (en)	2002-12-19	2004-07-08	Pfizer Inc.	2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
JP2006526025A (ja) *	2003-05-28	2006-11-16	エントレメッドインコーポレイテッド	抗血管新生剤
NZ592039A (en)	2003-08-27	2013-03-28	Ophthotech Corp	Combination therapy for the treatment of ocular neovascular disorders
EP1660504B1 (en)	2003-08-29	2008-10-29	Pfizer Inc.	Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents
PT2213661E (pt)	2003-09-26	2011-12-15	Exelixis Inc	Moduladores de c-met e métodos de uso
KR100872204B1 (ko) *	2003-10-15	2008-12-09	오에스아이 파마슈티컬스, 인코포레이티드	이미다조피라진 티로신 키나제 억제제
CN102225926A (zh)	2003-11-07	2011-10-26	诺华疫苗和诊断公司	具有改进药物特性的喹啉酮类化合物的药学上可接受的盐
AU2004293443A1 (en)	2003-11-19	2005-06-09	Signal Pharmaceuticals, Llc.	Indazole Compounds and methods of use thereof as protein kinase inhibitors
US7875624B2 (en)	2004-02-20	2011-01-25	Novartis Vaccines And Diagnostics, Inc.	Modulating and measuring cellular adhesion
US20070004689A1 (en) *	2004-03-12	2007-01-04	Agoston Gregory E	Antiangiogenic agents
US7498322B2 (en) *	2004-03-12	2009-03-03	Entremed, Inc.	Antiangiogenic agents
TWI378934B (en) *	2004-04-02	2012-12-11	Osi Pharm Inc	6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
TW200613306A (en)	2004-07-20	2006-05-01	Osi Pharm Inc	Imidazotriazines as protein kinase inhibitors
PL1805175T3 (pl)	2004-10-14	2008-08-29	Hoffmann La Roche	Nowe azaindolotiazolinony jako środki przeciwrakowe
WO2006058298A2 (en) *	2004-11-29	2006-06-01	Entremed, Inc.	A method of administering anti-angiogenic agents and a method of treating disease using same
CA2593005A1 (en) *	2005-01-03	2006-07-13	Myriad Genetics Inc.	Pharmaceutical compounds as activators of caspases and inducers of apoptosis and the use thereof
DOP2006000051A (es)	2005-02-24	2006-08-31	Lilly Co Eli	Inhibidores de vegf-r2 y métodos
US7304074B2 (en)	2005-04-05	2007-12-04	Hoffmann-La Roche Inc.	Substituted 1,5-naphthyridine azolinones
US20060264439A1 (en) *	2005-05-17	2006-11-23	Supergen, Inc.	Inhibitors of polo-like kinase-1
JP5545925B2 (ja)	2005-05-17	2014-07-09	ノバルティスアーゲー	ヘテロ環化合物の合成方法
MX2007014782A (es)	2005-05-23	2008-02-19	Novartis Ag	Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
US7566721B2 (en) *	2005-08-08	2009-07-28	Osi Pharmaceuticals, Inc.	Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
US20070185069A1 (en) *	2005-11-14	2007-08-09	Plum Stacy M	Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
RU2433826C2 (ru)	2005-11-29	2011-11-20	Новартис Аг	Композиции хинолинонов
AR057960A1 (es)	2005-12-02	2007-12-26	Osi Pharm Inc	Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) *	2005-12-19	2013-11-05	OSI Pharmaceuticals, LLC	Combination cancer therapy
US20070176403A1 (en) *	2006-02-01	2007-08-02	Dennis Calderone	Air adjustable seat
WO2007109312A2 (en) *	2006-03-20	2007-09-27	Entremed, Inc.	Disease modifying anti-arthritic activity of 2-methoxyestradiol
US20070258976A1 (en) *	2006-05-04	2007-11-08	Ward Keith W	Combination Therapy for Diseases Involving Angiogenesis
US20080234243A1 (en) *	2007-01-31	2008-09-25	Lavallee Theresa M	Method of treating amyloidosis mediated diseases
US20080190689A1 (en) *	2007-02-12	2008-08-14	Ballard Ebbin C	Inserts for engine exhaust systems
JP2011510018A (ja) *	2008-01-18	2011-03-31	オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド	癌治療のためのイミダゾピラジノール誘導体
EP2283020B8 (en) *	2008-05-19	2012-12-12	OSI Pharmaceuticals, LLC	Substituted imidazopyr-and imidazotri-azines
SG173014A1 (en)	2009-01-16	2011-08-29	Exelixis Inc	Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
WO2010123792A1 (en)	2009-04-20	2010-10-28	Osi Pharmaceuticals, Inc.	Preparation of c-pyrazine-methylamines
EP2427192A1 (en) *	2009-05-07	2012-03-14	OSI Pharmaceuticals, LLC	Use of osi-906 for treating adrenocortical carcinoma
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20110189174A1 (en) *	2010-02-01	2011-08-04	Afshin Shafiee	Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
US10968290B2 (en)	2017-03-28	2021-04-06	Exxonmobil Chemical Patents Inc.	Metallocene-catalyzed polyalpha-olefins
WO2019157169A1 (en)	2018-02-12	2019-08-15	Exxonmobil Chemical Patents Inc.	Catalyst systems and processes for poly alpha-olefin having high vinylidene content
US11078308B2 (en)	2018-02-12	2021-08-03	Exxonmobil Chemical Patents Inc.	Processes to produce poly alpha-olefin trimers
US11021553B2 (en)	2018-02-12	2021-06-01	Exxonmobil Chemical Patents Inc.	Metallocene dimer selective catalysts and processes to produce poly alpha-olefin dimers
WO2019210026A1 (en)	2018-04-26	2019-10-31	Exxonmobil Chemical Patents Inc.	Non-coordinating anion type activators containing cation having large alkyl groups
US11059791B2 (en)	2019-04-25	2021-07-13	Exxonmobil Chemical Patents Inc.	Non-coordinating anion type benzimidazolium activators
US12344696B2 (en)	2019-08-09	2025-07-01	Exxonmobil Chemical Patents Inc.	Process to produce low viscosity polyalphaolefins using non-aromatic-hydrocarbon soluble activators
CN112694474B (zh) *	2019-10-23	2022-03-18	四川大学	吲唑类衍生物及其制备方法和用途
EP4051656A1 (en)	2019-10-28	2022-09-07	ExxonMobil Chemical Patents Inc.	Dimer selective metallocene catalysts, non-aromatic hydrocarbon soluble activators, and processes to produce poly alpha-olefin oligmers therewith
US11572423B2 (en)	2019-12-11	2023-02-07	Exxonmobil Chemicals Patents Inc.	Processes for introduction of liquid activators in olefin polymerization reactions
US11584707B2 (en)	2019-12-16	2023-02-21	Exxonmobil Chemical Patents Inc.	Non-coordinating anion type activators containing cation having aryldiamine groups and uses thereof
WO2021173361A1 (en)	2020-02-24	2021-09-02	Exxonmobil Chemical Patents Inc.	Ansa-bis(inden-2-yl) catalysts for producing vinylidene-terminated polyalphaolefins
US11746163B2 (en)	2021-01-05	2023-09-05	Exxonmobil Chemical Patents Inc.	Isohexane-soluble unsaturated alkyl anilinium tetrakis(perfluoroaryl)borate activators
CN119638634B (zh) *	2023-09-18	2026-01-30	上海赛默罗生物科技有限公司	噌啉-2-氧化物类化合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2594438B1 (fr)	1986-02-14	1990-01-26	Labaz Sanofi Nv	Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
US5215988A (en)	1986-02-14	1993-06-01	Sanofi	Aminoalkoxyphenyl derivatives, process of preparation and compositions containing the same
US5182291A (en)	1986-02-14	1993-01-26	Sanofi	Pyrozala-pyridyl aminoabkoxyphenol compounds
IL87181A (en)	1987-08-07	1993-08-18	Sanofi Sa	Aminoalkoxyphenyl derivatives, their preparation and pharmaceutical and veterinary compositions containing them
IL89029A (en) *	1988-01-29	1993-01-31	Lilly Co Eli	Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
EP0888310B1 (en) *	1996-03-15	2005-09-07	AstraZeneca AB	Cinnoline derivatives and use as medicine

1997
- 1997-03-11 EP EP97906290A patent/EP0888310B1/en not_active Expired - Lifetime
- 1997-03-11 US US09/142,839 patent/US6514971B1/en not_active Expired - Fee Related
- 1997-03-11 AU AU21030/97A patent/AU2103097A/en not_active Abandoned
- 1997-03-11 DE DE69734149T patent/DE69734149T2/de not_active Expired - Fee Related
- 1997-03-11 WO PCT/GB1997/000650 patent/WO1997034876A1/en not_active Ceased
- 1997-03-11 JP JP9533220A patent/JP2000506880A/ja not_active Ceased
2002
- 2002-12-05 US US10/310,074 patent/US7087602B2/en not_active Expired - Fee Related

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002522535A (ja) *	1998-08-11	2002-07-23	ノバルティスアクチエンゲゼルシャフト	血管形成阻害活性を有するイソキノリン誘導体
JP2008512375A (ja) *	2004-09-03	2008-04-24	メモリファーマセチカルコーポレーション	精神医学的又は神経学的症候群の治療用のホスホジエステラーゼ１０阻害剤としての４−置換４，６−ジアルコキシ−シンノリン誘導体

Also Published As

Publication number	Publication date
EP0888310B1 (en)	2005-09-07
DE69734149T2 (de)	2006-07-06
US20030199513A1 (en)	2003-10-23
DE69734149D1 (de)	2005-10-13
US7087602B2 (en)	2006-08-08
EP0888310A1 (en)	1999-01-07
US6514971B1 (en)	2003-02-04
AU2103097A (en)	1997-10-10
WO1997034876A1 (en)	1997-09-25

Legal Events

Date	Code	Title	Description
2004-02-19	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040128
2004-02-19	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040128
2005-06-30	A711	Notification of change in applicant	Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050606
2005-06-30	A72	Notification of change in name of applicant	Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20050606
2005-07-21	RD02	Notification of acceptance of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20050704
2005-07-21	RD04	Notification of resignation of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20050704
2007-12-18	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071218
2008-02-05	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080205
2008-05-29	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080507
2008-06-16	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080616
2008-06-26	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080604
2008-07-14	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080714
2008-07-24	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080704
2008-08-19	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080819
2008-12-11	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081119
2009-08-04	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090804
2009-12-10	A313	Final decision of rejection without a dissenting response from the applicant	Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20091123
2010-01-12	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100112

Publication	Publication Date	Title
JP2000506880A (ja)	2000-06-06	シンノリン誘導体及びその使用
CA2362715C (en)	2010-10-19	Quinazoline derivatives as angiogenesis inhibitors
JP4959049B2 (ja)	2012-06-20	血管新生阻害剤としてのオキシインドリルキナゾリン誘導体
JP4464466B2 (ja)	2010-05-19	４―アニリノキナゾリン誘導体
US7262201B1 (en)	2007-08-28	Quinazoline derivatives
KR100834823B1 (ko)	2008-06-09	신놀린 화합물
JP2001500890A (ja)	2001-01-23	Ｖｅｇｆのような成長因子の作用を阻害するキノリン誘導体
SK108798A3 (en)	1999-01-11	Quinazoline derivatives as vegf inhibitors, preparation method thereof and pharmaceutical composition containing them
US20060148819A1 (en)	2006-07-06	Chemical compounds
AU2001276521A1 (en)	2002-05-16	Cinnoline compounds
HK1078579A (en)	2006-03-17	Quinazoline derivatives as angiogenesis inhibitors and intermediates therefore
HK1130477A (en)	2009-12-31	Quinazoline derivatives as angiogenesis inhibitors

JP2000506880A - シンノリン誘導体及びその使用 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (3)

Publications (2)

Family

ID=8225232

Family Applications (1)

Country Status (6)

Cited By (2)

Families Citing this family (96)

Family Cites Families (6)

Cited By (2)

Also Published As

Similar Documents

Legal Events